生物制剂治疗慢性鼻窦炎伴鼻息肉的临床效果与应答时间:真实世界经验
这项双中心回顾性研究纳入2023年4月至12月在两家意大利医院治疗的33例重度未控制慢性鼻窦炎伴鼻息肉患者,比较度普利尤单抗、奥马珠单抗和美泊利单抗的临床效果与应答时间;三种生物制剂均显著改善生活质量,度普利尤单抗鼻息肉评分改善最快最持久。
要点
- 三种生物制剂从基线至9个月均显著改善SNOT-22评分,组间无显著差异。
- 度普利尤单抗自4周起即显著降低鼻息肉评分,奥马珠单抗和美泊利单抗至6个月才显著降低。
- 度普利尤单抗组嗅觉功能显著改善,嗅觉丧失患者从64.3%降至9个月时28.6%。
核心结论
- 度普利尤单抗、奥马珠单抗和美泊利单抗均显著改善慢性鼻窦炎伴鼻息肉患者的生活质量并缩小鼻息肉,其中度普利尤单抗应答最快。
- 这些发现支持生物制剂在真实世界环境中治疗重度慢性鼻窦炎伴鼻息肉的有效性。
研究设计与样本
- 双中心回顾性研究,纳入2023年4月至12月在两家意大利医院治疗的33例患者。
- 纳入标准遵循EPOS 2020指南,聚焦成人双侧鼻息肉、有内镜鼻窦手术史且存在2型炎症证据者。
- 患者按AIFA方案自行注射生物制剂,在基线、4周、3、6和9个月评估结局。
- 结局指标包括SNOT-22生活质量、鼻息肉评分(NPS)鼻息肉大小和Sniffin' Sticks-12嗅觉功能。
主要发现
- 三个治疗组(度普利尤单抗、奥马珠单抗、美泊利单抗)从基线至9个月SNOT-22评分均显著改善,组间无显著差异。
- 度普利尤单抗组NPS改善最快最持久,自4周起即观察到显著降低。
- 奥马珠单抗和美泊利单抗组至6个月时NPS才显著降低。
- 度普利尤单抗组嗅觉功能显著改善,嗅觉丧失患者从64.3%降至9个月时28.6%。
- 哮喘控制测试(ACT)评分在所有组均改善。
关键数值与推荐
- 纳入标准遵循EPOS 2020指南,聚焦成人双侧鼻息肉、有内镜鼻窦手术史且存在2型炎症证据者。
- 患者按AIFA方案自行注射生物制剂。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a challenging condition often managed with biologic therapies. This study compares the clinical effects and response times of dupilumab, omalizumab, and mepolizumab in Italian patients with severe uncontrolled CRSwNP. METHODS: This bicentric, retrospective study included 33 patients treated at two Italian hospitals between April and December 2023. Inclusion criteria followed EPOS 2020 guidelines, focusing on adults with bilateral polyposis, history of endoscopic sinus surgery, and evidence of type 2 inflammation. Patients self-administered biologics according to AIFA protocols. Outcomes were assessed using SNOT-22 for quality of life, Nasal Polyp Score (NPS) for polyp size, and Sniffin' Sticks-12 for olfactory function at baseline, 4 weeks, 3, 6, and 9 months. RESULTS: All three treatment groups (dupilumab, omalizumab, mepolizumab) showed significant improvements in SNOT-22 scores from baseline to 9 months, with no significant differences between groups. Dupilumab showed the most rapid and sustained improvement in NPS, with significant reductions observed from 4 weeks onward. Both omalizumab and mepolizumab showed significant NPS reductions by 6 months. Olfactory function improved significantly in the dupilumab group, with a notable decrease in anosmic patients from 64.3% to 28.6% at 9 months. Asthma control, measured by Asthma Control Test (ACT) scores, improved across all groups. CONCLUSION: Dupilumab, omalizumab, and mepolizumab significantly improve quality of life and reduce nasal polyp size in CRSwNP patients, with dupilumab showing the fastest response. These findings support the effectiveness of biologics in real-world settings for managing severe CRSwNP. LEVEL OF EVIDENCE: 3 Laryngoscope, 135:1628-1635, 2025.
引用
- De Santis S, Galassi S, Cambi J, et al. Clinical Effects and Response Time of Biological Drugs in Chronic Rhinosinusitis with Nasal Polyps Patients: Real-life Experience. Laryngoscope. 2024. PMID: 39651676. doi:10.1002/lary.31948
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。